Connect with us

Technology

Mixtape podcast: Making technology accessible for everyone – Yahoo Finance Australia

Welcome back to Mixtape, the TechCrunch podcast that examines diversity, inclusion and the human labor that drives tech. This week, Megan moderated a panel …

Published

on

post featured image

SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December 6th, in conjunction with participation at the 2020 American Society of Hematology (ASH) Annual Meeting. The Aptose management team reviewed the current clinical status of CG-806, Aptoses oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor currently in two Phase 1 a/b trials, one trial in…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending